

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. - 88. (Canceled)

89. (Currently amended) A method for treating acute myeloid leukemia (AML) in a mammal, comprising administering to said mammal a therapeutically effective amount ~~amounts~~ of a combination of active compounds, which consists of a first active compound and a second active compound, wherein the first active compound is [(i)] a compound selected from the group consisting of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) and pharmaceutically acceptable salts thereof; and the second active compound is [(ii)] all trans retinoic acid.

90. (Currently amended) The method according to claim 89, wherein the first active compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] or a pharmaceutically acceptable salt thereof.

91. (Currently amended) The method according to claim 89, wherein the first active compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-

benzamide (Roflumilast-N-Oxide) or a pharmaceutically acceptable salt thereof.

92. (Currently amended) A treatment combination for acute myeloid leukemia (AML) comprising a combination of active compounds, which consists of a first active compound and a second active compound, wherein the first active compound is [(i)] a compound selected from the group consisting of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) and pharmaceutically acceptable salts thereof; and the second active compound is [(ii)] all trans retinoic acid.

93. (Currently amended) The treatment combination according to claim 92, wherein the first active compound of component (i) is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] or a pharmaceutically acceptable salt thereof.

94. (Currently amended) The treatment combination according to claim 92, wherein the first active compound of component (i) is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) or a pharmaceutically acceptable salt thereof.

95. (New) The method according to claim 89, wherein the first active compound is

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST].

96. (New) The method according to claim 89, wherein the first active compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide).

97. (New) The treatment combination according to claim 92, wherein the first active compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST].

98. (New) The treatment combination according to claim 92, wherein the first active compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide).